Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Poor adherence to oral bisphosphonate therapy remains a major challenge in the treatment of osteoporosis, substantially reducing therapeutic efficacy. While reminder interventions have been proposed as a method to enhance adherence, evidence remains limited. This study aimed to evaluate the impact of written and verbal reminders on medication adherence compared to standard patient care over a 12-month period in a real-world clinical setting. In this randomized controlled study, 180 postmenopausal women diagnosed with osteoporosis were assigned to one of three groups: standard care (control), written reminder, or verbal reminder. Interventions were administered at five standardized time points. Adherence was defined as intake of ≥80% of prescribed weekly doses (≥42 out of 52 doses) and a ≥35% reduction in serum C-terminal telopeptide of type I collagen (CTX) levels from baseline to 12 months. No significant differences in adherence rates were observed between groups: 53.2% in the control group, 52.0% in the written reminder group, and 52.7% in the verbal reminder group (χ = 0.014; p = 0.993). Changes in bone mineral density and serum CTX levels were also comparable across groups. The implementation of standardized written or verbal reminder strategy did not result in a statistically significant improvement in adherence to oral bisphosphonate therapy. Further studies are needed to investigate the reasons for low adherence to treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267344PMC
http://dx.doi.org/10.1007/s00223-025-01405-6DOI Listing

Publication Analysis

Top Keywords

oral bisphosphonate
12
verbal reminder
12
adherence
8
postmenopausal women
8
adherence oral
8
bisphosphonate therapy
8
reminder interventions
8
written verbal
8
written reminder
8
ctx levels
8

Similar Publications

Complex regional pain syndrome (CRPS) is a debilitating chronic pain condition that may develop after fractures, surgery, or soft tissue trauma. It is characterized by pain disproportionate to the initial injury, often accompanied by sensory, motor, autonomic, and trophic changes. Despite extensive research, pathophysiology remains unclear, and treatment approaches are varied, with inconsistent supporting evidence.

View Article and Find Full Text PDF

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication in patients undergoing long-term bisphosphonate therapy, while our knowledge on the pathogenesis of BRONJ is far from sufficient. Gamma delta (γδ) T cells predominantly distribute in mucosal tissues and play an important role in both immune modulation and bone metabolism; however, the mechanism of γδ T cells in the pathogenesis of BRONJ has not been elucidated. Here, we induced BRONJ-like lesions in wild-type (WT) and T-cell receptor delta-deficient (TCRδ) mice via intraperitoneal zoledronate injection.

View Article and Find Full Text PDF

Unlabelled: We examined characteristics of patients in Ontario, Canada, initiating publicly funded zoledronic acid for osteoporosis from 2006 to 2021. Most patients had prior osteoporosis treatments, with those previously using oral bisphosphonates more likely to receive a second dose. Understanding treatment decisions and patient beliefs is key for future research.

View Article and Find Full Text PDF

Medication-Related Osteonecrosis of the Jaw induced by a CDK 4/6 inhibitor (Palbociclib) in a patient who was naïve to Antiresorptive Bone Therapy: A Case Report.

Oral Surg Oral Med Oral Pathol Oral Radiol

August 2025

Service d'Odontologie, CHU Clermont-Ferrand, Clermont-Ferrand, France; Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM, Neuro-Dol, Clermont-Ferrand, France. Electronic address:

Medication-related osteonecrosis of the jaw (MRONJ) is a well-documented adverse effect initially linked to antiresorptive agents such as bisphosphonates. Over time, other drug classes have been associated with MRONJ: monoclonal antibodies targeting RANK ligand, monoclonal antibodies targeting VEGF, tyrosine kinase inhibitors, and mammalian target of rapamycin (mTOR) inhibitors. This article presents the case of an 83-year-old female patient referred to the maxillofacial surgery department due to a submental cutaneous fistula with purulent discharge and localized pain.

View Article and Find Full Text PDF